GlassScriptPhysician profile
Lucy R Canaday
NPI 1811958028
$531.04
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $505 · 2020: $26.15.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $159.74 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $146.46 | 2019 | |
| Amgen INC. | $83.41 | 2019 | |
| Sanofi-Aventis U.S. LLC | $27.46 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $25.57 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $19.52 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $15.29 | 2019 | |
| Glaxosmithkline, LLC. | $14.97 | 2019 | |
| Grifols USA, LLC | $13.08 | 2019 | |
| Lilly USA, LLC | $13.01 | 2019 | |
| Shire North American Group INC | $12.53 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lucy Canaday listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.